salmeterol xinafoate has been researched along with Pneumonia in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avorn, J; Feldman, WB; Kesselheim, AS; Russo, M; Wang, SV | 1 |
| Chang, TY; Chien, JY; Dong, YH; Lin, FJ; Wu, CH | 1 |
| Gill, TM; Leo-Summers, LS; Van Ness, PH; Vaz Fragoso, CA | 1 |
| Goike, H; Janson, C; Johansson, G; Jörgensen, L; Larsson, K; Lisspers, KH; Ställberg, B; Stratelis, G | 1 |
| Cates, CJ; Poole, P; Welsh, EJ | 2 |
| Abbasnejad, M; Boskabady, MH; Gholamnezhad, Z; Hosseini, M; Khazdair, MR | 1 |
| Heires, AJ; Nordgren, TM; Poole, JA; Romberger, DJ; Toews, ML; West, WW; Wyatt, TA | 1 |
| Anderson, JA; Calverley, PM; Celli, B; Crim, C; Ferguson, GT; Jenkins, C; Jones, PW; Vestbo, J; Willits, LR; Yates, JC | 1 |
| Anderson, JA; Calverley, PM; Celli, B; Ferguson, GT; Jenkins, CR; Jones, PW; Vestbo, J; Willits, LR; Yates, JC | 1 |
| Brown, J; Davis, K; Mapel, D; Miller, D; Schum, M; Yood, M | 1 |
| Calverley, PMA; Hagan, G; Riley, JH; Seemungal, TAR; Stockley, RA; Wedzicha, JA; Willits, LR | 1 |
| Beeh, KM; Fabbri, LM; Glaab, T; Hederer, B; Rabe, KF; Rutten-van Mölken, MP; Schmidt, H; Vogelmeier, C | 1 |
| Edwards, SJ; Gray, J; Halpin, DM; Morais, J; Singh, D | 1 |
| Lasserson, TJ; Nannini, LJ; Poole, P | 1 |
| de Vos, AF; Florquin, S; Jansen, HM; Maris, NA; Pater, JM; van der Poll, T; van der Sluijs, KF | 1 |
| Altman, LC; Potter-Perigo, S; Tsoi, C; Wight, TN; Wilkinson, TS | 1 |
| Allegra, L; Ambrosetti, U; Piatti, G; Santus, P | 1 |
| Duerden, M | 1 |
| Calhoun, WJ; Hinton, KL; Kratzenberg, JJ | 1 |
4 review(s) available for salmeterol xinafoate and Pneumonia
| Article | Year |
|---|---|
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Bronchodilator Agents; Drug Therapy, Combination; Fluticasone; Humans; Patient Dropouts; Pneumonia; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Albuterol; Androstadienes; Bronchodilator Agents; Drug Therapy, Combination; Fluticasone; Humans; Patient Dropouts; Pneumonia; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2010 |
Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Bronchodilator Agents; Budesonide; Drug Therapy, Combination; Ethanolamines; Fluticasone; Formoterol Fumarate; Glucocorticoids; Humans; Pneumonia; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Sample Size | 2011 |
Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Albuterol; Androstadienes; Bronchodilator Agents; Budesonide; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluticasone; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Pneumonia; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Salmeterol Xinafoate | 2012 |
7 trial(s) available for salmeterol xinafoate and Pneumonia
| Article | Year |
|---|---|
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Adult; Androstadienes; Asthma; Bronchodilator Agents; Cohort Studies; Drug Combinations; Fluticasone; Fluticasone-Salmeterol Drug Combination; Humans; Pneumonia; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate | 2023 |
Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Androstadienes; Budesonide; Cohort Studies; Ethanolamines; Fluticasone; Formoterol Fumarate; Glucocorticoids; Humans; Pneumonia; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate | 2013 |
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Bronchodilator Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluticasone; Humans; Male; Middle Aged; Pneumonia; Pulmonary Disease, Chronic Obstructive; Risk Factors; Salmeterol Xinafoate | 2009 |
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
Topics: Aged; Albuterol; Androstadienes; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone; Forced Expiratory Volume; Humans; Male; Middle Aged; Pneumonia; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Salmeterol Xinafoate; Smoking | 2009 |
Reported pneumonia in patients with COPD: findings from the INSPIRE study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Albuterol; Androstadienes; Bronchodilator Agents; C-Reactive Protein; Double-Blind Method; Female; Fluticasone; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pneumonia; Pulmonary Disease, Chronic Obstructive; Risk Factors; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2011 |
Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Bronchodilator Agents; Cholinergic Antagonists; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pneumonia; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2011 |
The effect of salmeterol on markers of airway inflammation following segmental allergen challenge.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Allergens; Analysis of Variance; Asthma; Biomarkers; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Pneumonia; Probability; Reference Values; Respiratory Function Tests; Salmeterol Xinafoate; Treatment Outcome | 2001 |
9 other study(ies) available for salmeterol xinafoate and Pneumonia
| Article | Year |
|---|---|
Comparative Safety and Effectiveness of Inhaled Corticosteroid and Long-Acting β
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Bronchodilator Agents; Budesonide; Drug Combinations; Drug Therapy, Combination; Female; Fluticasone; Formoterol Fumarate; Glucocorticoids; Humans; Male; Metered Dose Inhalers; Middle Aged; Pneumonia; Propensity Score; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Salmeterol Xinafoate; Taiwan | 2020 |
Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).
Topics: Aged; Bronchodilator Agents; Cardiovascular Diseases; Female; Fluticasone; Fluticasone-Salmeterol Drug Combination; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pneumonia; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Severity of Illness Index; Spirometry | 2019 |
Effect of fluticasone and salmeterol on tracheal responsiveness to ovalbumin and lung inflammation, administrated during and after sensitization.
Topics: Albuterol; Androstadienes; Animals; Fluticasone; Guinea Pigs; Organ Culture Techniques; Ovalbumin; Pneumonia; Random Allocation; Salmeterol Xinafoate; Trachea; Treatment Outcome | 2014 |
β2-Adrenergic agonists attenuate organic dust-induced lung inflammation.
Topics: Adrenergic beta-2 Receptor Agonists; Air Pollutants; Albuterol; Animals; Cell Line; Cytokines; Drug Evaluation, Preclinical; Dust; Humans; Male; Mice; Mice, Inbred C57BL; Pneumonia; Respiratory Mucosa; Salmeterol Xinafoate | 2016 |
Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Case-Control Studies; Delayed-Action Preparations; Drug Therapy, Combination; Female; Fluticasone; Humans; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Pneumonia; Pulmonary Disease, Chronic Obstructive; Risk Factors; Salmeterol Xinafoate; Severity of Illness Index | 2010 |
Salmeterol, a beta2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Animals; Bronchodilator Agents; CD11b Antigen; Chemotaxis, Leukocyte; Female; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neutrophils; Pneumonia; Pulmonary Alveoli; Receptors, Adrenergic, beta-2; Salmeterol Xinafoate; Tumor Necrosis Factor-alpha | 2004 |
Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts.
Topics: Albuterol; Androstadienes; Anti-Inflammatory Agents; Asthma; Bronchi; Cells, Cultured; Cytokines; Drug Interactions; Fibroblasts; Fluticasone; Glucosamine; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Inflammation Mediators; Interleukin-1; Lung; Pneumonia; RNA, Messenger; Salmeterol Xinafoate; Th1 Cells; Th2 Cells; Transferases; Tumor Necrosis Factor-alpha | 2004 |
Effects of salmeterol on cilia and mucus in COPD and pneumonia patients.
Topics: Albuterol; Cilia; Community-Acquired Infections; Female; Humans; Male; Mucus; Pneumonia; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate | 2005 |
Prevention of death in COPD.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Bronchodilator Agents; Data Interpretation, Statistical; Drug Therapy, Combination; Fluticasone; Humans; Pneumonia; Pulmonary Disease, Chronic Obstructive; Salmeterol Xinafoate | 2007 |